Loading organizations...
Tasso develops and commercializes patient-centric blood collection solutions for convenient at-home diagnostic testing. The company's core technology enables individuals to self-collect blood samples with minimal discomfort, moving diagnostic processes out of traditional clinical settings. These devices utilize a virtually painless method to collect high-quality blood samples suitable for a variety of laboratory analyses, making health monitoring more accessible.
The company was founded in 2014 by Ben Casavant, Ben Moga, and Erwin Berthier, emerging from their work on microfluidics and blood collection technologies. Their foundational insight centered on the need to improve patient experience and access to diagnostic testing, driven by the limitations and invasiveness of conventional venipuncture. They aimed to create a solution that empowers individuals to participate more actively in their healthcare journey.
Tasso’s products primarily serve individuals and healthcare providers seeking more flexible and less invasive options for diagnostic testing. The company envisions a future where diagnostic testing is seamlessly integrated into daily life, allowing for earlier detection, more frequent monitoring, and improved health outcomes. Its mission is to bring diagnostic testing directly to the home, enhancing overall patient care and convenience.
Tasso has raised $123.1M across 3 funding rounds.
Tasso has raised $123.1M in total across 3 funding rounds.
Tasso, Inc. is a Seattle-based healthcare technology company developing patient-centric, clinical-grade blood collection devices and end-to-end platforms that enable simple, virtually painless at-home blood sampling.[1][2][5][6] It primarily serves clinical researchers, biopharmaceutical companies, healthcare providers, and patients in decentralized clinical trials, post-approval studies, and genetic research, solving the problem of inconvenient, painful traditional blood draws by bringing reliable testing anywhere, anytime to boost patient engagement, retention, and access to diverse populations.[1][2][3][5] Key products include the Tasso+ lancet for whole liquid blood collection compatible with standard tubes, the Tasso Mini for frequent or sensitive sampling, and services like Tasso Care® for prescreening and logistics platforms handling shipping, tracking, and lab integration.[4][5][6] The company shows strong growth momentum through partnerships with ARUP Laboratories, UBC, Parkinson's Foundation, and a Japan joint venture approval in 2025, alongside citations in over 100 peer-reviewed publications.[1][2][3][4][5]
Tasso was co-founded by Erwin Berthier, PhD (Chief Technology Officer) and Ben Casavant, PhD (CEO), leveraging their expertise to pioneer remote blood collection.[1][3] The idea emerged from a need to transform the outdated blood draw process into something patient-friendly, enabling healthcare "anywhere, anytime," with early development funded by grants, investments, and co-development deals.[1][2] Pivotal moments include partnerships starting around 2023 with UBC for post-approval research, 2024 collaboration with Parkinson's Foundation for genetic studies, 2025 ARUP alliance for decentralized trials, and September 2025 regulatory approval in Japan via Tasso-SNBL joint venture, marking international expansion.[1][2][3][4] Headquartered in Seattle as a privately held company, Tasso has evolved from device innovation to a full-service platform cited in clinical trials.[5]
Tasso rides the wave of decentralized clinical trials (DCTs) and remote patient monitoring, accelerated by post-COVID demand for accessible healthcare and personalized medicine.[1][2][5] Timing is ideal amid rising biopharma needs for diverse participant data, improved retention (up to 30-50% higher in DCTs per studies), and regulatory support for at-home testing, countering traditional lab burdens.[2][3] Market forces like aging populations, telemedicine growth, and precision diagnostics favor Tasso, enabling broader genetic research (e.g., Parkinson's) and efficient post-approval studies.[3] It influences the ecosystem by democratizing blood testing, partnering with labs and foundations to expand trial access and pave the way for predictive analytics.[1][6]
Tasso is poised to dominate at-home blood collection as DCTs become standard, with expansions into preventive medicine, international markets like Japan, and AI-integrated analytics via its API ecosystem.[4][5] Trends like whole-genome sequencing, real-world evidence demands, and hybrid care models will propel growth, potentially through more pharma deals and device iterations for wearables. Its influence may evolve from niche innovator to infrastructure provider, enabling global health equity in research—transforming how we "bring healthcare anywhere, anytime" as promised.[1][2]
Tasso has raised $123.1M in total across 3 funding rounds.
Tasso's investors include Anurag Kondapalli, Cedars-Sinai, D. E. Shaw group, Foresite Capital, Hambrecht Ducera Growth Ventures, InCube Ventures, J2 Ventures, Merck, Senvest Management, Silicon Valley Bank, Elizabeth Hambrecht, Muna Bhanji.
Tasso has raised $123.1M across 3 funding rounds. Most recently, it raised $100.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $100M Series B | Anurag Kondapalli | Cedars Sinai, D. E. Shaw Group, Foresite Capital, Hambrecht Ducera Growth Ventures, InCube Ventures, J2 Ventures, Merck, Senvest Management, Silicon Valley Bank | Announced |
| Jul 22, 2020 | $17M Series A | Elizabeth Hambrecht | Cedars Sinai, Foresite Capital, Muna Bhanji, Techstars, Vertical Venture Partners | Announced |
| Mar 5, 2019 | $6.1M Venture Round | Brad Corona | Cedars Sinai, Techstars | Announced |
